Resumo

ROMERO, Inês et al. Desprescrever” nos Doentes em Fim de Vida: Um Guia para Melhorar a Prática ClínicaDeprescribing” In End of Life Patients: A Guide to Improve Clinical Practice. Medicina Interna [online]. 2018, vol.25, n.1, pp.45-87. ISSN 0872-671X.  https://doi.org/10.24950/rspmi/Revisao/139/1/2018.

Deprescribing consists on a systematic evaluation of the potential risks and benefits of each drug for a given patient, considering the clinical condition and vital prognosis. This process must be part of every patient’s care plan but most importantly in patients at the end of life, i.e., the last 12 months of life, consisting in a matter of great pertinence in the scope of Palliative Care. Drugs with a time to benefit that exceeds the patient’s estimated life expectancy should be discontinued-mostly drugs given as primary prevention, like statins. The maintenance of other pharmacological groups can be indicated, provided that the goals of care adjustment is guaranteed (e.g.: antimicrobials, anticoagulants, proton pump inhibitors and hypoglycemic agents). The deprescribing act intends to avoid or reduce polypharmacy, thus minimizing potential iatrogenic events and the therapeutic burden which takes special relevance at the end of life.

Palavras-chave : Deprescriptions; Inappropriate Prescribing; Polypharmacy; Terminal Care.

        · resumo em Português     · texto em Português     · Português ( pdf )